What does BrightSpring Health Services do?
BrightSpring Health Services, Inc. is a Nasdaq-listed home- and community-based healthcare platform serving medically complex Senior and Specialty populations. Rather than operating hospitals, it delivers pharmacy, clinical, rehabilitation, personal-care, and related services in homes, community settings, senior-living facilities, skilled-nursing facilities, hospices, and physician-directed care pathways. The company’s official company overview describes a national platform built around lower-cost settings and specialized or chronic-care needs.
Who does the platform serve?
BrightSpring’s economic relevance comes from the intensity, not merely the number, of patients it serves. As of June 2026, official offering materials described more than 475,000 patients served daily through approximately 12,400 clinical providers and pharmacists across all 50 states. These patients often use several services over long periods, creating opportunities for longitudinal medication management, home health, rehabilitation, and supportive care. The platform is reimbursed largely by Medicare, Medicaid, commercial insurers, pharmacy benefit managers, healthcare facilities, and private-pay sources.
| Identity | Company-specific fact | Why it matters |
|---|---|---|
| Listing | Nasdaq Global Select Market, ticker BTSG | Public-market reporting began after the January 2024 IPO. |
| Core model | Complementary Pharmacy Solutions and Provider Services | The model links high-frequency pharmacy activity with higher-touch clinical services. |
| Reach | All 50 states; more than 475,000 patients dailyJune 2026 offering materials | National scale supports payer access, procurement, referrals, and de novo expansion. |
| Workforce | Approximately 12,400 clinical providers and pharmacistsJune 2026 | Labor availability and productivity directly affect growth and margins. |
What do the two reportable segments include?
How does BrightSpring make money?
BrightSpring earns product revenue when its pharmacies dispense medicines and service revenue when clinicians or caregivers deliver reimbursable care. The pharmacy segment is much larger by revenue because specialty drugs can carry high acquisition costs and high invoice values. Provider Services is smaller but structurally more labor-intensive and has a higher gross-margin percentage. The key analytical point is that revenue scale alone does not identify the best business: a specialty prescription can add substantial revenue with modest percentage margin, while a home-health episode adds less revenue but more gross profit per revenue dollar.
Where does revenue come from?
| Revenue stream | Q1 2026 evidence | Economic interpretation |
|---|---|---|
| Infusion and specialty pharmacy | $2.644 billion, up 35.5% year over year | Growth was driven by higher volume in certain specialty branded drugs; limited-distribution access is strategically important. |
| Home and community pharmacy | $527.1 million, down 9.2% | The Inflation Reduction Act and drug-pricing changes pressured this line, illustrating policy sensitivity. |
| Home health care | $265.7 million, up 48.9% | Acquired branches and higher census expanded the largest Provider Services line. |
| Rehab and personal care | $176.7 million combined | These services broaden the continuum but rely on local labor availability and reimbursement rates. |
Why does reimbursement mix matter?
Government programs and managed-care contracts influence both price and utilization. Medicaid rates vary by state; Medicare home-health and hospice rules can change case-mix economics; PBMs influence pharmacy reimbursement and fees; manufacturers determine access to limited-distribution medicines. BrightSpring therefore has limited freedom to raise prices across the portfolio. Its practical defense is operating efficiency, purchasing scale, clinical quality, and shifting mix toward services or therapies where the company has differentiated access.
Which turning points created today’s BrightSpring platform?
BrightSpring is best understood as an acquisition-built healthcare network that has recently begun simplifying its portfolio. Its history matters because the current strengths—national reach, specialty-pharmacy access, and cross-service referrals—also create integration, leverage, goodwill, and governance considerations.
-
1974Predecessor operations began. The long operating history established community-based service capabilities and state-by-state regulatory experience.
-
2017KKR and Walgreens Boots Alliance acquired PharMerica, creating the pharmacy foundation that now dominates revenue.
-
2019The acquisition of BrightSpring Health Holdings combined provider operations with PharMerica and produced the current company name and integrated model.
-
2024The company completed an IPO of 53.3 million common shares at $13.00 and issued 8.0 million tangible equity units, expanding public ownership and refinancing capacity.
-
2025BrightSpring acquired 107 home-health and hospice branches from the Amedisys and LHC transaction, accelerating Provider Services scale.
-
March 2026The $835 million gross sale of Community Living closed, generating $810.9 million of cash proceeds after adjustments and costs and sharpening the focus on pharmacy, home health, rehabilitation, and personal care.
-
June 2026A 15.0 million-share secondary offering further reduced KKR’s stake while BrightSpring repurchased about 1.03 million shares, continuing the transition from sponsor control toward a broader public float.
Why did the 2017-2019 combination matter?
PharMerica supplied purchasing, dispensing, and payer relationships; BrightSpring’s provider network supplied patient access and recurring clinical touchpoints. The combination created a strategic thesis that one platform could coordinate medication and care for complex patients more effectively than isolated providers. Official filings note that the company already delivers multiple pharmacy and provider services to about 9,000 patients, leaving a large gap between current overlap and the hundreds of thousands served daily.
What did the IPO and portfolio reshaping change?
The IPO increased financial flexibility but did not immediately eliminate sponsor influence or leverage. The Community Living sale was more decisive operationally: it removed a large supportive-care business from continuing operations, supplied cash, lowered leverage, and made reported growth more representative of the retained platform. The official divestiture announcement frames the transaction as a focus on complementary pharmacy and provider health solutions.
What does BrightSpring’s latest quarter show?
The newest available reported period is the quarter ended March 31, 2026; second-quarter results were scheduled for July 31, 2026 and were not yet available as of this analysis. BrightSpring’s Q1 2026 earnings release and Form 10-Q show broad growth in both segments and substantially faster profit growth than revenue growth.
What changed in Q1 2026?
| Metric | Q1 2026 | Q1 2025 | Interpretation |
|---|---|---|---|
| Revenue | $3.614B | $2.878B | Growth of 25.6% reflected specialty-pharmacy volume and provider expansion. |
| Gross profit | $482.2M | $338.4M | Growth of 42.5% exceeded revenue growth, showing favorable mix and cost performance. |
| Operating income | $121.4M | $50.7M | Operating margin rose to about 3.4% from 1.8%. |
| Continuing net income | $74.3M | $9.2M | Interest expense declined while operating profit expanded. |
| Diluted EPS, continuing operations | $0.34 | $0.05 | Earnings growth outpaced dilution in the period. |
| Operating cash flow | $122.9M | $101.6M | Cash flow includes discontinued operations and should not be treated as a pure continuing-operations measure. |
Which operating KPIs explain the growth?
Prescription count fell 1.4% to 10.73 million, yet revenue per prescription rose 27.0% to $295.56 and gross profit per prescription rose 49.5% to $28.03. That combination indicates a powerful specialty-drug mix effect. In Provider Services, home-health average daily census increased 52.3% to 46,066, rehabilitation persons served rose 13.8% to 7,620, and personal-care persons served increased 1.4% to 16,079. The quarter therefore combined mix-led pharmacy economics with acquisition- and volume-led provider growth.
Why are pharmacy mix and provider density the central strategic tension?
BrightSpring’s headline growth can be excellent while underlying volume is mixed. Specialty drugs increase revenue per script, but they also increase cost of goods and can make revenue growth look stronger than unit growth. Provider Services has the opposite profile: labor, local branches, and census growth determine economics, and operating leverage emerges when acquired or de novo locations reach efficient scale.
Why does specialty mix improve dollars but constrain percentage margins?
Pharmacy Solutions generated $300.8 million of gross profit on $3.171 billion of Q1 2026 revenue, a gross margin of about 9.5%. Provider Services generated $181.4 million of gross profit on $442.4 million of revenue, about 41.0%. This is not evidence that pharmacy is unattractive; rather, it shows that revenue is an imperfect denominator when expensive specialty medicines are passed through the income statement. Researchers should track gross profit per script, segment EBITDA, and access to limited-distribution drugs alongside revenue.
How does provider expansion change the economics?
Home health is now the largest retained provider service, helped by the 107 acquired branches. In Q1 2026, home health contributed about 60.1% of Provider Services revenue, personal care 23.0%, and rehabilitation 16.9%. Acquisitions contributed $78.5 million of the segment’s $96.4 million year-over-year revenue increase, while organic volume and rate changes contributed about $17.9 million. The strategic test is whether BrightSpring can integrate branches, retain clinicians, and create referral density without allowing corporate overhead or working capital to rise at the same pace.
What gives BrightSpring a competitive advantage?
BrightSpring’s moat is not a consumer brand or patent portfolio. It is a combination of regulated operating licenses, manufacturer access, payer contracts, referral relationships, national purchasing scale, clinical workforce, data systems, and local service density. The company reported 149 limited-distribution oncology drugs in market and another 18 expected to launch over the following 12 to 18 months in its 2025 annual report. Such access can be valuable because manufacturers select only a limited group of pharmacies capable of complex distribution, patient support, compliance, and clinical coordination.
Which competitors pressure each segment?
| Competitive arena | Named or structural rivals | BrightSpring’s response |
|---|---|---|
| Specialty and infusion pharmacy | Option Care Health; CVS/Coram; Cigna’s Accredo; UnitedHealth’s Optum Specialty Pharmacy; regional providers | Limited-distribution access, oncology specialization, clinical support, and nationwide reach. |
| Long-term-care pharmacy | CVS’s Omnicare, facility-owned pharmacies, and local operators | Scale purchasing, facility relationships, dispensing infrastructure, and medication-management services. |
| Home health and personal care | National chains, hospital-affiliated networks, and many local agencies | Branch density, referral networks, quality scores, broad payer participation, and cross-service coordination. |
| Labor | Hospitals, pharmacies, clinics, and other community-care employers | Recruitment, retention, scheduling productivity, and career development are operating necessities. |
Why is integration difficult to copy?
A new entrant can open a local home-care agency in some states, and a large insurer or retailer may possess greater capital. Replicating the full platform is harder because each layer requires separate licenses, clinical protocols, billing systems, distribution relationships, compliance infrastructure, and referral trust. BrightSpring also invests about $200 million annually in quality, compliance, and safety according to its company materials. The defensibility is therefore cumulative rather than absolute: each capability strengthens the others, but execution failures in one layer can weaken the network.
How financially strong is BrightSpring?
The 2025 fiscal year established a much stronger earnings and cash-flow baseline. The company’s full-year 2025 results reported $12.911 billion of continuing-operations revenue, $1.518 billion of gross profit, $104.8 million of net income, $490 million of operating cash flow, and $618 million of adjusted EBITDA. The 2025 Form 10-K provides the balance-sheet and risk context behind those headline figures.
What do cash flow, leverage, and asset quality show?
| Financial indicator | Official figure | Analytical reading |
|---|---|---|
| FY2025 revenue | $12.911B | Up 28.2%; specialty mix and acquisitions were major drivers. |
| FY2025 operating cash flow | $490.0M | A large improvement from $24.0M in FY2024, but working-capital volatility remains important. |
| FY2025 property and equipment purchases | $95.5M | Operating cash less capex was approximately $394.5M before acquisitions and financing. |
| Debt | $2.570BDecember 31, 2025 | Meaningful leverage, though down from $2.683B one year earlier. |
| Goodwill | $2.546BDecember 31, 2025 | About 39.7% of total assets, reflecting acquisition history and impairment sensitivity. |
| Liquidity | $1.366BMarch 31, 2026 | Included $888.8M cash and $477.1M available under revolving and letter-of-credit facilities. |
How does capital allocation support growth?
BrightSpring deploys capital through acquisitions, de novo locations, technology, working capital, debt reduction, and opportunistic repurchases rather than dividends. FY2025 acquisitions used $204.6 million of cash, and Q1 2026 acquisitions used another $42.2 million. The Community Living sale produced $810.9 million of cash proceeds in Q1 2026, while the company spent $60.0 million repurchasing 1.46 million shares alongside the March secondary offering. In June, it authorized a further purchase of about 1.03 million shares from another sponsor-led offering.
Who owns BrightSpring stock, and how is control changing?
BrightSpring began public life with substantial private-equity influence. The investor base is now becoming more dispersed through repeated KKR secondary offerings, while large asset managers and the chief executive retain meaningful positions. The latest comprehensive institutional table is the 2026 proxy statement, based largely on ownership reported around December 31, 2025 and shares outstanding on March 30, 2026. A newer June 2026 offering prospectus updates KKR and management positions after the latest sale.
Who has economic and voting influence?
| Holder or group | Reported stake | Source period | Why it matters |
|---|---|---|---|
| KKR Stockholder | 27.15M shares; 13.8% | After June 2026 offering and repurchase | Still influential, but materially below the 21.7% proxy stake and far below pre-IPO control. |
| FMR LLC | 22.91M shares; 11.9% | Proxy disclosure | Large institutional ownership increases scrutiny of execution and liquidity. |
| BlackRock | 18.13M shares; 9.4% | December 31, 2025 ownership | A major passive and institutional voice in governance. |
| Vanguard | 12.53M shares; 6.5% | Proxy disclosure | Supports a more diversified public float as sponsor ownership declines. |
| T. Rowe Price Associates | 10.18M shares; 5.3% | Proxy disclosure | Another active institutional holder with long-term performance sensitivity. |
| Jon Rousseau, CEO | 4.29M shares; 2.2% | After June 2026 offering | Meaningful personal exposure aligns leadership with equity value, while option and RSU structures also matter. |
What does management compensation signal?
The proxy shows a performance framework weighted 75% to financial objectives and 25% to a quality index for the continuing named executive officers. The plan requires a minimum EBITDA gate before funding. This design is strategically coherent for a healthcare operator: growth and EBITDA matter, but quality performance must remain visible because reimbursement, referrals, compliance, and brand trust depend on clinical outcomes. The governance risk is that non-GAAP EBITDA can reward acquisition and adjustment-heavy growth unless the board also monitors cash conversion, leverage, integration, and patient outcomes.
What opportunities and risks could reshape BrightSpring’s outlook?
The opportunity set is substantial because complex patients consume a disproportionate share of U.S. healthcare spending and often receive fragmented care. BrightSpring can grow by winning specialty-drug access, opening locations, integrating acquired branches, expanding value-based care, and serving more patients across multiple service lines. The company increased 2026 guidance after Q1 to revenue of $14.725 billion to $15.225 billion and adjusted EBITDA of $795 million to $825 million, excluding future acquisitions.
Which growth drivers have the clearest evidence?
Which risks connect directly to the financial statements?
| Risk | Financial line affected | Concrete monitoring signal |
|---|---|---|
| Medicare, Medicaid, PBM, and drug-pricing changes | Revenue per script, gross profit, service rates | Home and community pharmacy revenue fell 9.2% in Q1 2026, partly reflecting Inflation Reduction Act effects. |
| Labor shortages and wage inflation | Cost of services and Provider EBITDA | Home-health census growth must be matched by clinician recruitment and productive scheduling. |
| Loss of drug or manufacturer access | Specialty revenue and gross profit per script | Track the 149 in-market limited-distribution oncology drugs and 18-product launch pipeline. |
| Acquisition integration | SG&A, cash flow, goodwill, and leverage | Provider growth depends heavily on acquired branches; goodwill was $2.546B at FY2025. |
| Billing, collections, and payer audits | Accounts receivable and operating cash flow | Accounts receivable reached $1.114B at March 31, 2026, up from $989.7M at year-end. |
| Cybersecurity and patient-data exposure | Operating costs, liability, and reputation | The Audit Committee oversees cybersecurity; the 2025 10-K reported no incident then known to be materially affecting the company. |
What matters most for BrightSpring’s valuation and future monitoring?
A BrightSpring DCF should not extrapolate reported revenue growth mechanically. The pharmacy mix can raise revenue per script without equivalent unit growth, while provider acquisitions can raise census and EBITDA but require integration capital and working capital. The most decision-useful forecast separates Pharmacy Solutions and Provider Services, models gross profit rather than only revenue, and explicitly links prescriptions, revenue per script, provider census, reimbursement rates, labor cost, corporate expense, capex, and acquisitions.
The discount rate and terminal assumptions also need to reflect the company’s debt, regulatory exposure, sponsor transition, and acquisition-built balance sheet. A higher long-term margin is plausible if specialty access, home-health density, and corporate scale compound. A lower outcome is plausible if PBM economics, reimbursement policy, labor shortages, or integration costs absorb the growth. The company’s investor-relations page and official filings page are the most direct sources for monitoring those variables.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.